Diabetes is a chronic metabolic disease characterized by elevated blood glucose due to insufficient insulin production, ineffective insulin action, or both. Persistent hyperglycaemia can damage blood vessels, nerves, kidneys, eyes, and other organs over time. Type 2 diabetes accounts for the vast majority of diabetes cases.
Anthropic announced it will run its own preclinical drug-discovery programs for neglected and rare diseases and launched Claude Science, an AI workbench for researchers. The company has not named specific diseases or detailed how it would bring candidates to market.
A living insulin implant from Technion researchers achieved one year of steady blood sugar control in diabetic mice, while millions worldwide still lack access to insulin medication. Animal trials showed beta cells could auto-dose insulin, though immune barriers remain before human trials. Meanwhile, only about half of type 2 diabetes patients globally have access to needed insulin, with the problem affecting both low- and high-income countries.
The global insulin drugs and delivery devices market is dominated by three manufacturers supplying roughly 90% of volume, with biosimilar entry slowly eroding this oligopoly. The market is projected to see continued growth driven by rising diabetes prevalence, while pricing pressure from biosimilars and government policies accelerates. In the Middle East, the recombinant human insulin market is projected to expand at a 6–8% CAGR through 2035.
New rankings from WIPR and IAM Patent 1000 recognize top US patent firms and lawyers, highlighting expertise in pharmaceutical litigation, tech disputes, and strategic portfolio management amid shifting PTAB procedures and rising NPE campaigns in life sciences.
AstraZeneca is advancing its oral GLP-1 drug into Phase III trials while defending dapagliflozin patents in Australia. The company obtained an Australian court injunction against a generic competitor and has partnered with Evinova to use AI for clinical trials. India could be a future market for the oral GLP-1 drug pending global trial data.
At the ADA Scientific Sessions, Novo Nordisk's Wegovy pill surpassed 3 million prescriptions within five months, while Structure Therapeutics and AstraZeneca shared mid-stage GLP-1 data targeting a 2029 launch. The US FDA approved TRUQAP as the first targeted treatment for PTEN-deficient metastatic prostate cancer, reducing disease progression risk by 19% in the CAPItello-281 trial. Meanwhile, two major genomic atlas projects—a 4,098-genome infant gut bacteria catalog and Basecamp Research's Trillion Gene Atlas—aim to advance precision probiotics and AI-driven drug discovery, respectively.
The Delhi High Court ruled Dr. Reddy's can export semaglutide, finding Novo Nordisk's patent unenforceable. Dr. Reddy's plans to launch generic Wegovy at 60% discount pending approval.
MiniMed completed its $538 million IPO as its separation from Medtronic advances, with shares trading on the Nasdaq. Medtronic submitted the next-generation MiniMed Flex insulin pump to the FDA and reported a 14.8% year-over-year revenue increase for its Diabetes business. The full separation is expected to be complete by the end of calendar year 2026.
The Australian government announced an additional $387.4 million for CSIRO over four years and $12.7 million for eight quantum technology projects under the Critical Technologies Challenge Program, part of its broader National Quantum Strategy commitment.
The FDA announced new enforcement priorities on February 6, 2026, to restrict GLP-1 active pharmaceutical ingredients used in non-FDA-approved compounded drugs being mass-marketed. The action follows an August 2025 citizens' petition arguing that large-scale compounded semaglutide production poses public health risks including lack of immunogenicity assessments and misleading marketing practices.
| NCT ID | Title | Status | Phase |
|---|---|---|---|
| NCT07598656 |
Local Delivery of Lactobacillus Reuteri Probiotic as An Adjunct to Non-surgical Periodontal Therapy in Patients With Stage II, III, and IV Periodontitis and Type 2 Diabetes Mellitus |
COMPLETED | NA |
| NCT07591415 |
Validation of an App in the Elderly Population With Diabetes Mellitus. |
COMPLETED | NA |
| NCT07587437 |
Preoperative Use of a Magnetically Controlled Capsule Endoscopy in Patients Undergoing Bariatric Surgery |
ENROLLING_BY_INVITATION | NA |
| NCT07581106 |
Physical Activity During Pregnancy in Women With Pre-existing Diabetes |
NOT_YET_RECRUITING | |
| NCT07567170 |
Satisfaction of Specific Modes Related to Physical Activity in People Living With Type 1 Diabetes and Using an Hybrid Closed-loop System |
RECRUITING | NA |
| NCT07561541 |
Extended Oral Antibiotic Prophylaxis in Diabetic Fracture Patients |
RECRUITING | PHASE4 |
| NCT07560969 |
Addressing Food Access and Physical Activity to Improve Diabetes Prevention Outcomes Among Underserved African Americans |
NOT_YET_RECRUITING | NA |
| NCT07559292 |
Implementing Artificial Intelligence to Prevent Vision Loss From Diabetes |
ENROLLING_BY_INVITATION | NA |
| NCT07557914 |
Epalrestat Combined With HAIC, Donafenib and Tislelizumab as First-line Treatment for Patients With Unresectable HCC and Diabetes - A Multicenter, Prospective, Single-arm Clinical Study |
NOT_YET_RECRUITING | PHASE2 |
| NCT07555327 |
Clinical Observation of Renal Function Reactivation Following a GRAS-Based Protocol in Patients With Chronic Kidney Disease and Long-Term Renal Arrest. |
COMPLETED |
